1259TiP A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i).
Gasal, E Arance Fernandez, A Ascierto, P Atkinson, V Dummer, R Flaherty, K Grob, J Hansson, J Hassel, J Larkin, J
Gasal, E
Arance Fernandez, A
Ascierto, P
Atkinson, V
Dummer, R
Flaherty, K
Grob, J
Hansson, J
Hassel, J
Larkin, J
Citations
Altmetric:
Abstract
Description
Date
2017-09
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
1259TiP A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i). 2017, 28(suppl_5): Ann Oncol